+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oral antiplatelet therapy in the secondary prevention of atherothrombotic events



Oral antiplatelet therapy in the secondary prevention of atherothrombotic events



American Journal of Cardiovascular Drugs 9(3): 197-209



Atherothrombosis is the leading cause of death worldwide and has a large economic impact. It is a pathologic process related to atherosclerosis, which leads to adverse clinical manifestations, including acute coronary syndrome, cerebrovascular disease, and peripheral arterial disease. Patients with atherothrombosis are at heightened risk for recurrent ischemic events or death, and therefore, secondary prevention is an important goal in the treatment of these patients. Antiplatelet therapies available for long-term secondary prevention include aspirin (acetylsalicylic acid), extended-release dipyridamole plus aspirin, and clopidogrel. A number of clinical trials have demonstrated the benefit of combined antiplatelet therapy in secondary prevention, supporting the recommendations made in current published guidelines. Although the efficacy and safety of antiplatelet agents is well established and supported by clinical trials, their utilization rate in patients with atherothrombosis remains suboptimal. Quality improvement initiatives have demonstrated effectiveness in promoting the awareness and implementation of treatment guidelines. This article reviews the benefits and risks of antiplatelet therapy in patients with cardiovascular disease with the aim of spurring greater adherence to treatment recommendations and, thereby, better patient outcomes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054780423

Download citation: RISBibTeXText

PMID: 19463024

DOI: 10.1007/bf03256575


Related references

Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine 18(1): 10-15, 2016

Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents. Current Pharmaceutical Design 18(6): 850-860, 2012

Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents. Current Pharmaceutical Design 18(6): 850-860, 2012

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal 158(3): 335-341.E3, 2009

Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. PharmacoEconomics 25(12): 1063-1082, 2007

Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. Southern Medical Journal 101(3): 273-283, 2008

Antiplatelet therapy for secondary prevention of the complications of atherothrombotic disease. Consultant Pharmacist 19(9): 813-823, 2004

Antiplatelet Therapy for Secondary Prevention of the Complications of Atherothrombotic Disease. The Consultant Pharmacist 19(9): 813-823, 2004

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. Pharmacoeconomics 25(12): 1063-1082, 2007

Selection of a suitable patient population for new antiplatelet therapy from the large clinical trial database of the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-thrombolysis in myocardial infarction 50 (TRA-2P-TIMI50) trial. Circulation 131(12): 1041-1043, 2015

Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. Journal of Cardiovascular Pharmacology and Therapeutics 10(3): 153-161, 2005

Antiplatelet combinations for prevention of atherothrombotic events. Vascular Health and Risk Management 7: 23-30, 2011

Use of antiplatelet drugs in secondary prevention in patients with atherothrombotic disease. Comprehensive Therapy 32(3): 182-188, 2006

Use of antiplatelet drugs in secondary prevention in older persons with atherothrombotic disease. Journals of Gerontology. Series A Biological Sciences and Medical Sciences 62(5): 518-524, 2007

Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. PharmacoTherapy 29(7): 812-821, 2009